Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054390 | 0.88 | ADAMTS4 (0.43) | MTNR1AMTNR1BPIN1ADAMTS4EGFR | |
| SCHEMBL7616512 | 0.82 | MTNR1A (0.47) | MTNR1AMTNR1BPIN1ADAMTS4KDM4E | |
| SCHEMBL5054778 | 0.77 | CYP1A2 (0.45) | — | |
| SCHEMBL5053192 | 0.77 | CYP2D6 (0.53) | ALDH1A1 | |
| SCHEMBL8063568 | 0.77 | MTNR1A (0.46) | MTNR1AMTNR1BPIN1ADAMTS4EGFR | |
| SCHEMBL7604618 | 0.77 | EGFR (0.43) | EGFRPIK3CAKDM4EALDH1A1GAA | |
| SCHEMBL5060243 | 0.75 | ACP3 (0.44) | MTNR1AALDH1A1 | |
| SCHEMBL5054459 | 0.74 | KMT2A (0.50) | KDM4EALDH1A1GAA | |
| SCHEMBL5058003 | 0.73 | CYP1A2 (0.49) | — | |
| SCHEMBL5053033 | 0.73 | CYP1A2 (0.42) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |